(Q33379530)

English

A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Faruk Tas

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nese Guney

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Duygu Derin

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adnan Aydiner

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Erkan Topuz

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

156-160

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10147-007-0740-4

0 references

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP).

1 reference

https://pubmed.ncbi.nlm.nih.gov/18463961

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-007-0740-4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33379530&oldid=1990965120"